$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000140191419000090 Filed on November 12, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.490M	$1.450M	$1.470M
YoY Change	14.62%	22.88%	4.26%
% of Gross Profit
Research & Development	$2.370M	$1.966M	$2.513M
YoY Change	42.77%	35.93%	13.3%
% of Gross Profit
Depreciation & Amortization	$10.00K	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$3.860M	$3.419M	$3.982M
YoY Change	30.41%	30.4%	9.87%
Operating Profit		-$3.419M	-$3.982M
YoY Change		30.4%	9.87%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$10.00K	$25.47K	$30.00K
YoY Change	-125.0%	-45.95%	-29.62%
Pretax Income	-$3.870M	-$3.390M	-$3.950M
YoY Change	32.53%	31.91%	10.34%
Income Tax
% Of Pretax Income
Net Earnings	-$3.870M	-$3.393M	-$3.952M
YoY Change	32.53%	31.8%	10.34%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$214.4K	-$203.2K	-$245.2K
COMMON SHARES
Basic Shares Outstanding	16.68M shares	16.68M shares	16.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.780M	$2.440M	$5.630M
YoY Change	-29.81%	-74.42%	-54.78%
Cash & Equivalents	$4.780M	$2.435M	$5.600M
Short-Term Investments
Other Short-Term Assets	$1.110M	$770.0K	$440.0K
YoY Change		40.0%	25.71%
Inventory
Prepaid Expenses	$1.109M	$770.5K	$438.0K
Receivables
Other Receivables	$555.2K	$37.84K	$493.0K
Total Short-Term Assets	$6.444M	$3.243M	$6.562M
YoY Change	-11.0%	-68.11%	-48.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$63.53K	$5.905K	$7.081K
YoY Change	576.15%	-40.95%	-10.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$935.3K	$632.6K	$692.3K
YoY Change	61.83%	2.04%	4.89%
Total Long-Term Assets	$998.9K	$638.6K	$699.4K
YoY Change	70.06%	1.36%	5.97%
TOTAL ASSETS
Total Short-Term Assets	$6.444M	$3.243M	$6.562M
Total Long-Term Assets	$998.9K	$638.6K	$699.4K
Total Assets	$7.443M	$3.882M	$7.261M
YoY Change	-4.91%	-64.06%	-46.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.083M	$350.0K	$630.0K
YoY Change	135.63%	-70.83%	-50.39%
Accrued Expenses	$2.099M	$1.537M	$1.342M
YoY Change	232.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.612M	$1.889M	$1.974M
YoY Change	414.4%	57.4%	55.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$389.6K	$183.2K	$203.9K
YoY Change	3911.49%	1731.96%
Total Long-Term Liabilities	$389.6K	$183.2K	$203.9K
YoY Change	3911.49%	1731.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.612M	$1.889M	$1.974M
Total Long-Term Liabilities	$389.6K	$183.2K	$203.9K
Total Liabilities	$7.002M	$2.072M	$2.178M
YoY Change	536.1%	70.93%	71.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.02M	-$40.20M	-$36.80M
YoY Change	51.96%
Common Stock	$44.57M	$42.08M	$41.94M
YoY Change	24.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$440.8K	$1.810M	$5.083M
YoY Change
Total Liabilities & Shareholders Equity	$7.443M	$3.882M	$7.261M
YoY Change	-4.91%	-64.06%	-46.14%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	-$3.870M	-$3.393M	-$3.952M
YoY Change	32.53%	31.8%	10.34%
Depreciation, Depletion And Amortization	$10.00K	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$3.810M	-$3.180M	-$3.020M
YoY Change	40.59%	15.64%	12.27%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$6.140M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	$6.140M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.200M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	5.150M
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-3.810M	-3.180M	-3.020M
Cash From Investing Activities	6.140M	0.000	0.000
Cash From Financing Activities	0.000	0.000	5.150M
Net Change In Cash	2.330M	-3.180M	2.130M
YoY Change	-185.98%	9.66%	-167.62%
FREE CASH FLOW
Cash From Operating Activities	-$3.810M	-$3.180M	-$3.020M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$3.810M	-$3.180M	-$3.020M
YoY Change	40.59%	15.64%	12.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dare	Adjustments To Additional Paid In Capital Common Stock And Warrants Issued AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued	9377716	USD
CY2017Q3	dare	Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9900000	USD
CY2017Q3	dare	Business Combination Reverse Merger Unamortized Fair Value Of Stock Options BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions	3700000	USD
CY2018Q1	dare	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	10000000	USD
	dare	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	1100000	USD
	dare	Increase Decrease In Other Non Current Assets And Deferred Charges IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges	-105692	USD
	dare	Increase Decrease In Other Non Current Assets And Deferred Charges IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges	-138719	USD
CY2018Q3	dare	License Fee LicenseFee	0	USD
	dare	License Fee LicenseFee	350000	USD
CY2019Q3	dare	License Fee LicenseFee	133333	USD
	dare	License Fee LicenseFee	408333	USD
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	10114452	USD
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	5151702	USD
	dare	Non Cash Lease Expense NonCashLeaseExpense	0	USD
	dare	Non Cash Lease Expense NonCashLeaseExpense	10549	USD
	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39991	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	58538	USD
	dei	Entity Shell Company EntityShellCompany	false
	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2018Q1	dare	Percentage Of Aggregate Commission PercentageOfAggregateCommission	0.03
CY2018Q3	dare	Percentage Of Increase In Annual Base Rent PercentageOfIncreaseInAnnualBaseRent	0.04
CY2018Q1	dare	Research And Development Milestone Payment ResearchAndDevelopmentMilestonePayment	75000	USD
CY2019Q3	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0
	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0
	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y8M1D
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16683411	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Dare Bioscience, Inc.
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	459705	USD
CY2019Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	352243	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	631351	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1536587	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-96728	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-112402	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35791972	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	42077455	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1977617	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	135393	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	344712	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	77737	USD
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5356623	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5356623	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5575808	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5575808	shares
CY2018Q4	us-gaap	Assets Assets	7827387	USD
CY2019Q3	us-gaap	Assets Assets	3882018	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	7240023	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	3243465	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6805889	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2400000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2435120	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7559846	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9537463	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6805889	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2435120	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4370769	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	30333	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3500000.0	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3750833	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11422161	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16683411	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11422161	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16683411	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1143	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	1668	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2593196	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13882215	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3408456	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11202635	USD
CY2019Q3	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	1212766	USD
	us-gaap	Depreciation Depreciation	1263	USD
	us-gaap	Depreciation Depreciation	3491	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.32
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.76
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-59952	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-15674	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1175049	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3635413	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1318986	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3903545	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5200000	USD
CY2018Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5187519	USD
CY2019Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	32888	USD
CY2018Q2	us-gaap	Grants Receivable GrantsReceivable	1900000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-39803	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-107463	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	276062	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	905236	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-193495	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	8900	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-30463	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-203928	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	6802	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	238378	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	367409	USD
CY2019Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.07
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	208203	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	27665	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	67595	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	112943	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	25007	USD
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P37M
CY2018Q4	us-gaap	Liabilities Liabilities	1100767	USD
CY2019Q3	us-gaap	Liabilities Liabilities	2072026	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7827387	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3882018	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1091056	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1888830	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10114452	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5151702	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-518836	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7558047	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9500000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9506797	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-2574475	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-3393078	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10397367	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2574475	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13822263	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	173274	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	232000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13822263	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3393078	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11186961	USD
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	2621597	USD
	us-gaap	Operating Expenses OperatingExpenses	13923755	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	3418549	USD
	us-gaap	Operating Expenses OperatingExpenses	10484070	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2621597	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13923755	USD
CY2018Q3	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	8873	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	577968	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	632648	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-18721	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-59952	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-15378	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-15674	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3418549	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10484070	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	27038	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	81115	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	183196	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	241000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	92242	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	90954	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	27665	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	80905	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9711	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	183196	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	47122	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	101492	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25471	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	86703	USD
CY2018Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	31037	USD
CY2019Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	37839	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	237403	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	507000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11836	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	403097	USD
CY2019Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	770506	USD
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5200000	USD
	us-gaap	Profit Loss ProfitLoss	-13822263	USD
	us-gaap	Profit Loss ProfitLoss	-10397367	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9396	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5905	USD
	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	224665	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1446548	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4750823	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1966230	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6172192	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	507000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28969767	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40156729	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40200000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	231698	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	58538	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	344712	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.21
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.21
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0258
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0258
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	412471	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.23
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	70	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	508745	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	698000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.75
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1635790	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1824975	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.08
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.25
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	59.48
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.24
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.79
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5261250	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14756213	shares
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	800000	USD
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	789594	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11422161	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10499982	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16683411	shares
CY2018Q3	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
CY2019Q3	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	375000	shares
CY2019Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2018Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-3464	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	736735	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5151702	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	13292783	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	12217963	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	9583557	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	6726620	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	5083055	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1809992	USD

Files In Submission

Name	View Source	Status
0001401914-19-000090-index-headers.html	Edgar Link	pending
0001401914-19-000090-index.html	Edgar Link	pending
0001401914-19-000090.txt	Edgar Link	pending
0001401914-19-000090-xbrl.zip	Edgar Link	pending
dare-20190930.xml	Edgar Link	completed
dare-20190930.xsd	Edgar Link	pending
dare-20190930_cal.xml	Edgar Link	unprocessable
dare-20190930_def.xml	Edgar Link	unprocessable
dare-20190930_lab.xml	Edgar Link	unprocessable
dare-20190930_pre.xml	Edgar Link	unprocessable
dare-employeeperformancebo.htm	Edgar Link	pending
darebioinlinefullcolorrgb.jpg	Edgar Link	pending
dare_10qx20190930.htm	Edgar Link	pending
exhibit311_20190930.htm	Edgar Link	pending
exhibit312_20190930.htm	Edgar Link	pending
exhibit321_20190930.htm	Edgar Link	pending
exhibit322_20190930.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2019 Q4 Form 10-Q Financial Statement

#000140191419000090 Filed on November 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2019 Q4 Form 10-Q Financial Statement

#000140191419000090 Filed on November 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare